Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers Meeting Abstract
| Authors: | Schram, A. M.; Goto, K.; Kim, D. W.; Martin-Romano, P.; Ou, S. H. I.; O'Kane, G. M.; O'Reilly, E. M.; Umemoto, K.; Duruisseaux, M.; Neuzillet, C.; Opdam, F.; Ahnert, J. R.; Nagasaka, M.; Weinberg, B. A.; Macarulla, T.; Joe, A. K.; Ford, J.; Stalbovskaya, V.; Wasserman, E.; Drilon, A. E. |
| Abstract Title: | Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300110 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.105 |
| Notes: | Meeting Abstract: 105 -- Meeting also held virtually -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work